DAWN
HealthcareDay One Biopharmaceuticals, Inc. · Biotechnology · $2B
What is Day One Biopharmaceuticals, Inc.?
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with genetically defined cancers. Headquartered in Brisbane, California, the company is building a pipeline centered on precision oncology.
Day One generates value by advancing oral, targeted cancer therapies through clinical trials. Its lead program targets pediatric low-grade glioma, a historically underserved patient population. The company earns no product revenue yet — it operates on capital raised to fund research and clinical development, with commercialization dependent on regulatory approval of its lead asset.
Day One Biopharmaceuticals was incorporated in 2021 and is headquartered in Brisbane, California.
- DAY101 — oral brain-penetrant pan-RAF kinase inhibitor for pediatric low-grade glioma
- Pimasertib — oral MEK1/2 inhibitor in clinical development
- Genetically defined cancer targeting platform
- Pediatric oncology clinical programs
Is DAWN a Good Stock to Buy?
UQS Score rates DAWN as Below Average overall, reflecting the early-stage nature of its pipeline and the financial profile typical of pre-revenue biopharmaceutical companies.
The Growth pillar stands out as the clearest positive signal, consistent with a company advancing a lead asset through late-stage pediatric oncology trials. Risk is rated Neutral, suggesting the company's financial runway and operational profile are not extreme outliers for its stage.
Quality and Moat both register as Weak — expected for a clinical-stage company without approved products or durable revenue streams. Valuation is Elevated, meaning the market has priced in significant pipeline success.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account on UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does DAWN pay dividends?
No — Day One Biopharmaceuticals, Inc. does not currently pay a dividend.
DAWN does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. Available capital is directed toward clinical trials, regulatory activities, and pipeline development rather than shareholder distributions. Income-focused investors should note that a dividend is unlikely until the company achieves sustained product revenue.
When does DAWN report earnings?
Day One Biopharmaceuticals reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus on cash position, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline milestones and regulatory updates tend to drive more market attention than the income statement alone.
For the most recent quarter's results and pipeline updates, visit Day One Biopharmaceuticals' investor relations page directly.
DAWN Price History
-9.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Day One Biopharmaceuticals, Inc.?
Based on Day One Biopharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
DAWN Long-term Outlook
The fundamental outlook for DAWN is shaped primarily by clinical execution. A Good Growth pillar rating reflects meaningful near-term catalysts tied to DAY101's regulatory pathway. However, an Elevated Valuation pillar suggests the current share price embeds optimistic assumptions about approval and commercial uptake. Neutral Risk indicates the company is not in an unusually precarious position for its stage, but binary trial outcomes remain the dominant variable.
Growth drivers
- Potential regulatory approval and commercialization of DAY101 in pediatric low-grade glioma
- Expansion of the pipeline into additional genetically defined cancer indications
- Growing clinical and commercial interest in precision pediatric oncology
Key risks
- Clinical trial failure or regulatory setback for DAY101 would materially reset expectations
- Elevated valuation leaves limited margin of safety if pipeline timelines slip
- Pre-revenue status means continued dependence on capital markets for funding
DAWN vs Peers
Day One operates in a competitive precision medicine landscape alongside other clinical-stage and specialty biopharmaceutical companies.
Adaptive focuses on immune medicine using T-cell receptor sequencing, differentiating itself through a diagnostics-plus-therapeutics platform rather than a single oncology drug program.
Stoke targets genetic neurological diseases using RNA-based approaches, competing for investor attention in rare pediatric disease but with a distinct mechanism and patient population.
Sarepta is a more advanced rare disease company with approved products on the market, giving it a commercial revenue base that Day One has not yet achieved.
Frequently Asked Questions
What does Day One Biopharmaceuticals do?
Day One Biopharmaceuticals develops targeted, oral therapies for patients with genetically defined cancers. Its lead program, DAY101, is being studied in pediatric patients with relapsed or progressive low-grade glioma. The company is clinical-stage, meaning it does not yet have an approved product generating commercial revenue.
Does DAWN pay dividends?
No, DAWN does not pay a dividend. Clinical-stage biopharmaceutical companies typically reinvest all available capital into research and development. A dividend is unlikely until the company has approved products and a sustainable revenue base.
When does DAWN report earnings?
Day One Biopharmaceuticals reports on a quarterly cadence standard for US-listed companies. Because it is pre-revenue, reports center on cash runway and pipeline progress rather than traditional earnings. Check the company's investor relations page for the latest schedule.
Is DAWN a good stock to buy?
UQS Score rates DAWN as Below Average overall. The Growth pillar is a relative strength, but Quality and Moat are both Weak, and Valuation is Elevated. Whether DAWN fits a portfolio depends on an investor's risk tolerance for binary clinical outcomes and pre-revenue biotech exposure.
Is DAWN overvalued?
The UQS Valuation pillar for DAWN is rated Elevated, suggesting the market has priced in meaningful pipeline success. For a pre-revenue company, valuation is largely driven by clinical expectations rather than current financials. Pro members can view the detailed valuation metrics behind this rating.
How does DAWN compare to its competitors?
Compared to peers like Sarepta Therapeutics, which has approved products, Day One is earlier in its commercial journey. Adaptive Biotechnologies and Stoke Therapeutics share a clinical-stage profile but pursue different disease areas and mechanisms. The UQS platform scores each company independently across the same five pillars.
What is DAWN's market cap bracket?
DAWN is classified as a mid-cap stock. This places it in a range where institutional interest is meaningful but the company still carries the binary risk profile associated with clinical-stage biopharmaceuticals without a diversified product portfolio.
Who founded Day One Biopharmaceuticals?
Day One Biopharmaceuticals was incorporated in 2021. Founding and leadership details are publicly available through the company's official website and SEC filings, which provide the most accurate and up-to-date information on its executive history.
Is DAWN a long-term quality investment?
As a long-term quality indicator, UQS rates DAWN as Below Average. Weak Quality and Moat scores reflect the absence of approved products and durable competitive advantages today. Long-term quality potential depends heavily on whether DAY101 achieves regulatory approval and generates sustainable revenue.
What is the main competitive advantage of Day One Biopharmaceuticals?
Day One's differentiation lies in its focus on brain-penetrant, oral kinase inhibitors targeting pediatric cancers — a niche with limited approved options. If DAY101 gains approval, first-mover positioning in pediatric low-grade glioma could represent a meaningful, if narrow, competitive advantage.
Unlock Full DAWN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings for DAWN
- ✓Access detailed financial metrics behind the Quality and Valuation scores
- ✓Compare DAWN side-by-side with peers using standardized pillar scores
- ✓Track pipeline and risk signals with the complete analyst view
- ✓Get Pro access to scores across the full healthcare and biotech universe
Pro Analysis
DAWN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 32.3 | 11.7 | 37.0 | 55.3 | 60.5 | 0.0 | +0.4 |
| May 11, 2026 | 31.9 | 11.7 | 37.0 | 55.3 | 58.0 | 0.0 | +2.9 |
| May 10, 2026 | 29.0 | 0.0 | 37.0 | 55.3 | 58.0 | 0.0 | -2.9 |
| Apr 22, 2026 | 31.9 | 11.7 | 37.0 | 55.3 | 58.0 | 0.0 | -2.8 |
| Apr 2, 2026 | 34.7 | 11.7 | 37.0 | 69.1 | 58.0 | 0.0 | — |
DAWN — Pillar Breakdown
Quality
— 11.7/100 (25%)Day One Biopharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 55.3/100 (20%)Day One Biopharmaceuticals, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 60.5/100 (15%)Day One Biopharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Day One Biopharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 37/100 (25%)Day One Biopharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DAWN.
Score Composition
Financial Data
More Stock Analysis
How is the DAWN UQS Score Calculated?
The UQS (Unified Quality Score) for Day One Biopharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Day One Biopharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Day One Biopharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.